OpGen (NASDAQ: OPGN) is developing and deploying precision medicine tools for antibiotic stewardship management in global healthcare settings, adding real benefits to antimicrobial stewardship programs and assisting clinicians with more rapid information about life threatening infections. Using molecular testing and bioinformatics, OpGen offers a full portfolio of QuickFISH and Acuitas products including the MDRO Gene Test, the Resistome Test, microbial Whole Genome Sequence Analysis, and Acuitas Lighthouse MDRO Management System products. Its QuickFISH products are a suite of FDA-cleared and CE-marked diagnostics for rapid molecular testing of positive blood cultures designed to assure appropriate antibiotic therapy. For more information, visit the company’s website at www.opgen.com